

Selection and biochemical characterization of novel leishmanicidal molecules by virtual and biochemical screenings targeting *Leishmania* eukaryotic translation initiation factor 4A

Yosser Zina Abdelkrim

Institut Pasteur de Tunis, Tunisia.



Abstract

The identification of novel small and active molecules for the treatment of leishmaniasis constitutes a research priority. Here, we expand on previous *in silico* investigations and virtual screens of small molecules targeting the *Leishmania infantum* initiation factor 4A (Lief) as a potential drug target. Lief belongs to the DEAD-box family of RNA helicases. DEAD-box proteins contain a highly conserved core structure with a dumbbell shape containing two, linked domains with structural homology to that of recombinant protein A (RecA). This core structure confers an ATP-dependent RNA-binding affinity, an RNA-dependent ATPase activity and an ATP-dependent RNA unwinding activity. We used the ATPase activity to establish a colorimetric assay in microtiter plates to screen for molecules that inhibit Lief. We screened hundreds of molecules previously identified by virtual screenings for their ability to bind to sites on Lief that were important for the enzymatic activity. We discovered an interesting inhibitor: 6- α/β -aminocholestanol with an IC₅₀ value of $150 \pm 15 \mu\text{M}$ for $1 \mu\text{M}$ of Lief. This compound also inhibits the RNA helicase activity of Lief. The helicase assays and the ATPase competition experiments with the individual RecA-like domains and other proteins indicate that there are multiple binding sites on Lief, and that the primary binding site is on domain 1 involving conserved RNA-binding motifs. Two out of ten identified chemical analogues of 6- α/β -aminocholestanol (6- α -aminocholestanol and 6-ketocholestanol) showed inhibitor effects on the ATPase activity of Lief. Similar inhibitor effects were observed with mammalian eIF4A, but with different reaction profiles. All three molecules showed an anti-leishmanial activity against the promastigotes and the amastigotes of *L. infantum* parasites, and they showed non-significant toxicity toward macrophages. This study constitutes a first step towards the validation of Lief as a drug target. It demonstrates biochemical differences between the *Leishmania* and mammalian eIF4A proteins, most notably in ATPase assays that show that rocaglamide affects the two proteins differently. To conclude, this work delivers a promising leishmanicidal molecule: 6-aminocholestanol with IC₅₀ value lower than $1 \mu\text{M}$ on intracellular amastigotes, with little toxicity and with a selectivity index higher than 20. The 6-aminocholestanol constitutes a promising anti-*Leishmania* molecule that deserves further investigation.



Biography

Yosser Zina Abdelkrim is working as a professor in Institut Pasteur de Tunis in the Department of Parasitology. Her field of interest is Pharmaceutical, Biochemistry Parasitology.

Publication

2nd World Congress on Chemistry, Drug Design and Development | Prague, Czech Republic | July 20-21, 2020

Citation: Yosser Zina Abdelkrim, Selection and biochemical characterization of novel leishmanicidal molecules by virtual and biochemical screenings targeting *Leishmania* eukaryotic translation initiation factor 4A, Drug Design 2020, 2nd World Congress on Chemistry, Drug Design and Development, Prague, Czech Republic, July 20-21, 2020, 03